Standing Committee on Biotechnology Capabilities and National Security Needs | HQ003423NFOEASD18

Opportunity Information: Apply for HQ003423NFOEASD18

The Department of Defense, through Washington Headquarters Services, issued a discretionary grant opportunity (Funding Opportunity Number HQ003423NFOEASD18) titled "Standing Committee on Biotechnology Capabilities and National Security Needs." The effort is framed around a request from the National Commission on Emerging Biotechnology for the National Academy of Sciences to carry out work under an existing Standing Committee and an associated ad hoc consensus study committee focused on "Biotechnology Capabilities for National Security Needs." In practical terms, the government is funding a structured, expert-driven process to continuously track where biotechnology is heading, interpret what those developments mean for national security, and translate those insights into actionable guidance for government, industry, and academia.

A central theme of the opportunity is building an enduring capability to identify and assess "over-the-horizon" biotechnology developments. That language signals interest in more than near-term trends; it is about maintaining a sustained, repeatable ability to anticipate emerging scientific and technological advances before they are widely adopted. The committees are expected to consider how to spot early signals, evaluate potential impacts, and develop approaches for assessing both opportunities and risks as biotechnology evolves. This is meant to be a standing, ongoing function rather than a one-time snapshot, implying an emphasis on methods, frameworks, and institutional processes that can keep pace with rapid change.

Another major focus is developing innovative approaches to evaluating both traditional and non-traditional applications of emerging biotechnologies. "Traditional" applications might include areas like medical countermeasures, diagnostics, therapeutics, vaccines, and bioindustrial production, while "non-traditional" applications could extend to novel uses or combinations of technologies that do not fit established categories, including cross-domain applications that blur lines between civilian and defense use. The intent is to improve how the government and the broader research community assess biotechnology in a way that accounts for converging technologies, dual-use potential, and complex pathways from lab discovery to real-world deployment.

The opportunity also emphasizes improving communication of national security needs and requirements to industry and academia. This reflects a common gap: government agencies often have security-driven priorities, constraints, and mission requirements that do not naturally map onto how commercial firms or university labs plan research, product development, and investment. The committees are expected to examine what communication methods have worked, what has not, and how to better convey needs in ways that are understandable, actionable, and aligned with how external partners operate. This can include strategies for articulating requirements, shaping research agendas, creating clearer demand signals, and fostering partnerships that accelerate translation without undermining legitimate security concerns.

A further deliverable area is identifying exemplars of effective and ineffective regulatory processes that affect biotechnology transfer between government and commercial entities. The government is asking for concrete examples that illustrate how rules, compliance pathways, approvals, contracting mechanisms, and related oversight can either enable or slow the movement of biotechnology innovations across sectors. By calling for both effective and ineffective cases, the request is not limited to best practices; it also seeks lessons learned, bottlenecks, unintended consequences, and process failures that can inform improvements. The underlying objective is to understand how regulatory and policy environments influence speed, safety, competitiveness, and the ability to field capabilities relevant to national security.

To ground the discussion, the committees will use artificial intelligence and machine learning, along with experimental and laboratory automation in biotechnology R&D, as specific examples. These are highlighted because they are increasingly central to modern biotech development: AI/ML can accelerate discovery, design, and analysis, while automation can scale experimentation, increase throughput, and improve reproducibility. At the same time, these tools raise new questions about validation, transparency, security, workforce needs, and the pace at which capabilities can spread. By using AI/ML and lab automation as reference points, the committees can illustrate broader evaluation and governance challenges that apply across many emerging biotechnology areas.

From an administrative standpoint, this is a grant (not a contract) in the Science and Technology and other Research and Development category, listed under CFDA 12.599. The award ceiling is $700,000, with one expected award, indicating a single primary recipient tasked with convening and executing the committee work products. The posting dates show the opportunity was created on September 5, 2023, with an original closing date of September 12, 2023, reflecting a short application window typical of narrowly targeted or specialized solicitations. Eligibility is listed as "Others," with further clarification referenced in an additional eligibility field, which often indicates a limited pool of qualified entities or specific types of organizations capable of hosting a standing committee and producing consensus study outputs.

Overall, the grant is best understood as support for an expert committee-driven capability that continuously scans and assesses emerging biotechnology, improves methods for evaluating a wide range of biotech applications, strengthens how national security requirements are communicated to the innovation ecosystem, and draws evidence-based lessons from regulatory pathways that affect government-to-commercial technology transfer, using AI/ML-enabled biotech and lab automation as concrete anchors for the broader analysis.

• The Department of Defense, Washington Headquarters Services in the science and technology and other research and development sector is offering a public funding opportunity titled "Standing Committee on Biotechnology Capabilities and National Security Needs" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.599.
• This funding opportunity was created on Sep 05, 2023.
• Applicants must submit their applications by Sep 12, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $700,000.00 in funding.
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for HQ003423NFOEASD18

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: